Articles

Find an Article

Filter articles

Showing 601 to 610 of 675 results

Teaching old drugs new tricks

US30-09-2013

Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach.

Biopharmaceuticals: can India have its cake and eat it?

India31-08-2013

There has been much debate about whether there is a global deterioration of IP, and many commentators would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India.

EPO decision could trip up US patent defenders

EU31-08-2013

A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.

Spiral Genetics: clarifying the gene pool

US31-08-2013

In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP.

Accelerating and decelerating patent prosecution in Europe and the UK

EU, UK31-07-2013Matt Smith and Jonathan Wills

At some offices, the passage of a patent through the system is not quite as fast as applicants might hope—and at others it may be quicker than they would like. Matt Smith and Jonathan Wills outline the situation.

Keeping secrets: protecting the smallpox vaccine

31-07-2013

Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.

Current barriers to biotech in Brazil

Brazil31-07-2013Gabriel Di Blasi

Gabriel Di Blasi outlines the existing impediments to developing new biotechnology products in Brazil, and considers recent efforts to improve the situation.

A rare opportunity: aTyr Pharma and orphan drugs

US28-06-2013

As support for the study of rare diseases picks up, how does a good IP strategy bring orphan drugs to market? LSIPR spoke to aTyr Pharma’s chief executive John Mendlein to find out.

Quality control: biotech at the EPO

EU28-06-2013

The European Patent Office grants approximately 6,000 biotechnology patents per year. LSIPR spoke to Victor Kaas, director of biotechnology at the office, about how it faces the unique challenges of the industry.

Personalised medicine: patenting new drugs from old

28-06-2013Paul England

The law of patents and SPCs has yet to be tested in the context of medicines which can be used to treat specific groups of patients, as Paul England explains.

Showing 601 to 610 of 675 results

LSIPR